All News

steroid prednisone lab

Are You a High or Low Glucocorticoid Prescriber?

d Jack Cush, MD

A recent analysis shows thta glucocorticoids (GCs), usually recommended for short-term use in rheumatoid arthritis (RA), are variably used by rheumatologists, and that provider preference is a strong predictors of long-term glucocorticoid use.

Read Article
RheumNow Podcast square

RheumNow Podcast – Quackademia (10.15.2021)

d Jack Cush, MD

Dr. Jack Cush reviews the FDA approvals, news and the latest journal articles from the past week on RheumNow.com.

Read Article
morbidity,covid,heart,lung,brain

2021 Update to EULAR Points on Immunomodulatory Use in COVID-19

d Jack Cush, MD

EULAR has updated its recommendations (points to consider - PtC) for rheumatologists managing patients during COVID-19; now with 2 overarching principles and 12 PtC.

Read Article
aosd.CXR_.jpg (keep)

Still’s Disease Following COVID-19 Vaccination

d Jack Cush, MD

Both systemic onset juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease are acquired autoinflammatory disorders of uncertain etiology. Yet recent reports of AOSD onset and flare following COVID-19 vaccinations may have important mechanistic implications.

Read Article
In case you missed it: FDA Approves Avacopan for ANCA-Associated Vasculitis https://t.co/L7UwhYBaVY #RheumNow https://t.co/HypjLMLwjU

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Triple DMARD Rx - MSH vs MLH (Lef). 136 active #RA pts given OL MTX/SSZ/HCQ vs MTX/HCQ/LEF. Equal efficacy (EULAR-Good) was seen at wk 12 (54% vs 59%) and wk 24 (65% vs 62%) - hence LEF substitution was noninferior. https://t.co/F5CGj0w7Bh https://t.co/OuDMgNIKTA

Links:

Dr. John Cush RheumNow ( View Tweet)
For best practices in managing the Delta wave, the US would have done well to consult Puerto Rico US 26 cases/100,000 people, 19/100K hospitalized 57% vaccinated PR 3 cases/100,000 people, 3/100K hospitalized, 68% vaccinated https://t.co/kqlXBlmYpu
Eric Topol EricTopol ( View Tweet)
This 15-day-old boy developed this rash, which was diagnosed with neonatal lupus; anti-Ro and anti-La Abs were present, in both, mother and child. The mother never had had symptoms suggesting SLE or any autoimmune disease. The rash healed after 45 days; the boy is doing great😍 https://t.co/fYB0IzE7kY
Emilio Martin Mola emartinmola ( View Tweet)
In case you missed it…a popular read. Clinical Associations with Myositis Antibodies Read the full article on #RheumNow https://t.co/tzPU1scc8x https://t.co/pmmtmIuz31

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast titled Quackademia available for download. https://t.co/Y6Pqko1tYm https://t.co/Hm22p70d5e

Links:

Dr. John Cush RheumNow ( View Tweet)
Still’s Disease Following COVID-19 Vaccination https://t.co/23R41Pydve https://t.co/y0loTQuKBH

Links:

Dr. John Cush RheumNow ( View Tweet)
Fluorosis presenting as lower back pain and stiffness of the neck, shoulders, hips, yellowish-brown tooth discoloration, LOM of Cx spine, hips, shoulders. Pelvic Xrays showed osteosclerosis without sacroiliitis. T scores were +12.1 LS spine, alk phos =479 https://t.co/t2lmoudUIM https://t.co/6dWH0Rqhva

Links:

Dr. John Cush RheumNow ( View Tweet)
CXCL13 predicts worse Xray status in early #RA. Study of 158 pts, followed 11-years. Baseline CXCL13 correlated with Xray progression (ΔTSS) at 11 years. CXCL13 was superior to CRP, DAS28CRP, SJC28, CCP predicting 11-yr Xray damage https://t.co/1WAdZoYQ1P

Links:

Dr. John Cush RheumNow ( View Tweet)

Risk of anterior uveitis w/ secukinumab is equal to etanercept; but both inferior to mAb TNFi (infliximab, adalimumab) ~ 5000 Rx starts, AU risk/100PY = SEC 6.8; ETA 7.5; INFLIX 2.9; ADA 4. SEC has a 2.3 fold greater risk than ADA/INFX https://t.co/DB9G2mz4mN

Links:

Dr. John Cush RheumNow ( View Tweet)

Among 2359 RA & PsA pts (3169 TNFi courses 1778/1391), serious infection (SIE) rates were higher in RA 4.17/100PY vs PsA 2.16/100PY. PsA had 41% lower SIE risk (HR 0.59, p=0.004) - Registry data from the NOR-DMARD study https://t.co/llH07TFHOI

Links:

Dr. John Cush RheumNow ( View Tweet)

Retrospective study hospitalized new-onset systemic JIA (2008-19):52 children’s hospitals & 534 sJiAshows 29% rx w/ biologics & 58% steroids. Over time Biologic use increased & MTX decreased. Biologic correlated w/ Hi hospital volume, ICU stay, later years https://t.co/blbOps9zVQ

Links:

Dr. John Cush RheumNow ( View Tweet)

Comparative study of 46 AOSD, 9 MAS & 31 adult HLH pts, shows that serum IL-18 was signif higher in AOSD than HLH (closely correlates w/ ferritin, sIL-2R). IL-18, sIL-2R, ‘arthralgia or arthritis’ independently distinguished AOSD from HLH https://t.co/ZW6e78nEkh

Links:

Dr. John Cush RheumNow ( View Tweet)

Smoking worsens adult-onset Still’s disease. 185 AOSD pts, found 45 smokers who had higher risk of pericarditis (36 vs 16%), pleuritis (33 vs 14%), abd pain (18% vs 6%), higher systemic score (6.4 vs 5.4 ), More MAS (29% vs 6%), lung disease (18% vs 13%) https://t.co/ZKKhw1EbnD

Links:

Dr. John Cush RheumNow ( View Tweet)

Decline in the incidence of Behcets Dz? Between 2004 to 2017 Korea has seen BD decreased from 8.15/100K (2004) to 1.51/100K (2017), an 81.5% decrease, greater for women and middle-aged people, but no change survival or mortality https://t.co/tvZSSGMOH7

Links:

Dr. John Cush RheumNow ( View Tweet)

Congratulations to a great rheumatologist, Dr. Rita Jain, newly appointed Executive Vice President, Chief Medical Officer for ChemoCentryx, who's new C5a inhibitor avacopan (Tavneos) was just FDA approved for ANCA-assoc vasculitis! https://t.co/udhjSFF1Q0

Links:

Dr. John Cush RheumNow ( View Tweet)

×